- Short report
- Open Access
Acid mediates a prolonged antinociception via substance P signaling in acid-induced chronic widespread pain
Molecular Pain volume 10, Article number: 30 (2014)
Substance P is an important neuropeptide released from nociceptors to mediate pain signals. We recently revealed antinociceptive signaling by substance P in acid-sensing ion channel 3 (ASIC3)-expressing muscle nociceptors in a mouse model of acid-induced chronic widespread pain. However, methods to specifically trigger the substance P antinociception were still lacking.
Here we show that acid could induce antinociceptive signaling via substance P release in muscle. We prevented the intramuscular acid-induced hyperalgesia by pharmacological inhibition of ASIC3 and transient receptor potential V1 (TRPV1). The antinociceptive effect of non-ASIC3, non-TRPV1 acid signaling lasted for 2 days. The non-ASIC3, non-TRPV1 acid antinociception was largely abolished in mice lacking substance P. Moreover, pretreatment with substance P in muscle mimicked the acid antinociceptive effect and prevented the hyperalgesia induced by next-day acid injection.
Acid could mediate a prolonged antinociceptive signaling via the release of substance P from muscle afferent neurons in a non-ASIC3, non-TRPV1 manner.
Substance P (SP) is a neuropeptide released from nociceptors to mediate pain transmission centrally and neurogenic inflammation peripherally [1, 2]. Our recent study showed that release of SP from muscle nociceptive nerve fibers was antinociceptive in a mouse model of acid-induced chronic widespread pain . The unexpected antinociceptive role of SP was found exclusively in acid-sensing ion channel 3 (ASIC3)-expressing muscle nociceptors: SP acts on neurokinin 1 (NK1) receptors to reduce acid-induced depolarization via activation of an M-type potassium channel that is G protein-independent but tyrosine kinase-dependent. The inhibitory effect of SP could prevent the development of chronic widespread pain induced by repeated intramuscular acid insults.
Acid is effective in causing chronic muscle pain via activation of ASIC3 or transient receptor potential V1 (TRPV1) in muscle nociceptors [4–8]. The mouse model of acid-induced chronic widespread muscle pain was developed to mimic the clinical symptoms of fibromyalgia, exhibiting both chronic widespread pain and autonomic dysfunction [4, 9]. In this model, 2 injections (separated by 2 to 5 days) of pH4.0 acid saline to one side of the gastrocnemius muscle caused bilateral, long-lasting referred hyperalgesia in mouse hind paws. The first acid injection produces only transient hyperalgesia that diminished in 24 h, and the second acid injection 2 to 5 days later to the same muscle causes long-lasting hyperalgesia that lasts for more than 4 weeks. In mice lacking SP signaling by genetic ablation or pharmacological blockade in muscle, a single intramuscular acid injection is enough to produce long-lasting hyperalgesia . In contrast, an additional boost of SP with the second acid injection prevents the development of chronic widespread pain in wild-type mice that received the first acid injection.
The physiological mechanism underlying the SP-mediated inhibition of ASIC3 signaling might be therapeutically useful, because application of an NK1 agonist prevented the development of long-lasting hyperalgesia induced by a second acid injection; however, the beneficial effect of endogenous SP release was lost during the second acid challenge .
Here, we aimed to probe possible ways to trigger and enhance SP analgesia in the mouse model of chronic widespread pain.
Although ASIC3 and TRPV1 play major roles in acid-induced nociception in muscle pain models, accumulating evidence has shown that a subset of muscle nociceptors express other acid sensors, such as ASIC1a, ASIC1b, and ASIC2a [10–13]. Thus, we examined whether acid had other biological effects in muscle in a non-ASIC3, non-TRPV1 signaling pathway. We tested this hypothesis in the Sluka acid-induced chronic widespread pain model. We mixed acid saline (pH 4.0) with APETx2 (a selective ASIC3 antagonist)  and capsazepine (a selective TRPV1 antagonist)  for the first intramuscular injection of the dual acid-injection scheme. As expected, the mixture of APETx2 and capsazepine abolished the acid-induced transient hyperalgesia with the first injection; a second acid injection 5 days later induced only transient hyperalgesia (Figure 1A,B). The second acid injection even failed to induce transient hyperalgesia when administered 1 or 2 days after the first injection (Figure 1C,D). A possible explanation is that the acid had a prolonged antinociceptive effect in muscle via non-ASIC3, non-TRPV1 signaling in muscle afferent neurons.
We next probed whether the prolonged antinociceptive effect of non-ASIC3, non-TRPV1 acid signaling was mediated by SP release. We examined the effect of APETx2 and capsazepine on acid-induced hyperalgesia in mice lacking the tachykinin 1 gene (Tac1−/−; no SP and no neurokinin A production). APETx2 combined with capsazepine could abolish the acid-induced transient hyperalgesia during the first injection in Tac1−/− mice as in their wild-type littermates (Figure 2A,B). Intriguingly, Tac1−/− mice showed acid-induced chronic hyperalgesia (for 1 week) when the second acid injection was given the next day. Therefore, SP may play a key role in acid-induced prolonged antinociception in non-ASIC3, non-TRPV1 signaling in muscle afferent neurons. If so, SP alone should be able to reproduce the prolonged antinociceptive effect in the acid-induced chronic widespread pain model. Indeed, on pretreatment with an NK1-selective agonist, [Sar9,Met(O2)11]-substance P (SM-SP), 1 day before the acid injection, acid no longer induced hyperalgesia (Figure 2C,D). Just like non-ASIC3, non-TRPV1 acid signaling, the SM-SP-induced prolonged antinociceptive signaling did not last for 5 days. Five days after pretreatment with SM-SP, dual acid injections 5 days apart induced transient hyperalgesia at 4 h after the first acid injection and long-lasting hyperalgesia after the second acid injection at 5 days (Figure 2E).
Although acid is an effective algogen causing pain, especially muscle pain [16, 17], we report here an antinocieptive role for acid in a mouse model of chronic widespread pain. This acid-mediated antinociceptive pathway might act via a subset of acid-sensitive muscle afferent neurons that are neither ASIC3- nor TRPV1-positive to release SP. This finding expands our recent knowledge of SP antinociceptive signaling, which could have a prolonged inhibitory effect, lasting for 2 days, on muscle nociceptors.
Previously, we found that SP activated M-type potassium channels in muscle nociceptors in a G protein-independent manner and thus inhibited the ASIC3-induced inward current. The inhibitory effect of SP was reproduced in vivo, with abolished acid-induced chronic widespread pain on co-injection of SP with acid saline into the gastrocnemius muscle . In the acid-induced chronic widespread pain model, acid signaling seems to dominantly activate ASIC3 or TRPV1 to evoke a referred hyperalgesia in mouse hind paws and nociceptor priming [4, 8]. The results of the current study suggest that acid also activates receptors or ion channels in muscle afferent neurons that express neither ASIC3 nor TRPV1 to elicit the release of SP and limit the hyperalgesia to a transient phase. The possible acid sensors might be other members of the ASIC family (e.g., ASIC1a and ASIC2), which are also expressed in muscle afferent neurons . Alternatively, acid might activate a group of proton-sensing G protein-coupled receptors (e.g., G2A, GPR4, OGR1, and TDAG8) that are functionally coupled with ASIC3 [18–20]. Future studies should identify the molecular identity of the antinociceptive acid sensor(s), which will shed new insight for the development of analgesic drugs targeting chronic widespread muscle pain, such as in fibromyalgia.
We found that muscular SP signaling, endogenously released from muscle afferent neurons by acid challenge or exogenously injected, could silence muscle nociceptors from further firing in 2 days. How the G-protein-independent signaling with SP antinociception could last for 2 days remains unknown. The G protein-independent SP/NK1 signaling in muscle nociceptors might be as complicated as its G protein-dependent pathway in other cell types [21, 22]. Nevertheless, this knowledge is clinically useful because we can then develop strategies to prevent the development of chronic muscle pain caused by repeated muscle injury or ischemic insult.
Material and methods
We used male C57/BL6 mice (8 to 12 weeks old). All procedures were approved by the Institutional Animal Care and Use Committee of Academia Sinica and followed the Guide for the Use of Laboratory Animals (National Academy Press, Washington, DC). Mice lacking tachykinin 1, the gene encoding SP (Tac1−/−), were generated as previously described . Tac1+/+ and Tac1−/− mice were offspring of congenic C57BL6 Tac1+/− intercrosses.
The mouse model of acid-induced chronic widespread pain induced by repeated intramuscular acid injection was as described , with modification, and described previously . Briefly, mice received an intramuscular injection in the gastrocnemius muscle of acid containing 20 μL acid saline (pH 4.0) with or without APETx2 (20 pmol; Alomone, Jerusalem, Israel) and capsazepine (1 nmol; Torcis, Avonmouth, UK). Mechanical hyperalgesia of hind paws was measured by application of a 0.2-mN von Frey filament. The experimenter conducting the von Frey test had no information about the mouse genotypes or drug injections. In some studies, mice received pretreatment with an intramuscular injection of pH 7.4 saline or 40 μM [Sar9,Met(O2)11]-substance P (SM-SP; Sigma, St. Louis, MO) at 1 or 5 days before the acid injection.
The Mann–Whitney U test was used to compare withdrawal responses to the von Frey filament application in mice before acid or pH 7.4 saline injection (baseline) and at each time after intramuscular injection of acid (with or without drugs). P < 0.05 was considered statistically significant.
Acid-sensing ion channel 3
Transient receptor potential V1.
Hokfelt T, Petnow B, Wahren J: Substance P: a pioneer amongst neuropeptides. J Intern Med 2001, 249: 27–40.
Gangadharan V, Kuner R: Pain hypersensitivity mechanisms at a glance. Dis Model Mech 2013, 6: 889–895. 10.1242/dmm.011502
Lin CCJ, Chen WN, Chen CJ, Lin YW, Zimmer A, Chen CC: An antinociceptive role for substance P in acid-induced chronic muscle pain. Proc Natl Acad Sci USA 2012,109(2):E76-E83. 10.1073/pnas.1108903108
Sluka KA, Proce MP, Breese NM, Stucky CL, Wemmie JA, Welsh MJ: Chronic hyperalgesia induced by repeated acid injections in muscle is abolished by the loss of ASIC3, but not ASIC1. Pain 2003, 106: 229–239. 10.1016/S0304-3959(03)00269-0
Fujii Y, Ozaki N, Taguchi T, Mizumura K, Furukawa K, Sugiura Y: TRP channels and ASICs mediate mechanical hyperalgesia in models of inflammatory muscle pain and delayed onset muscle soreness. Pain 2008, 140: 292–304. 10.1016/j.pain.2008.08.013
Yen YT, Tu PH, Chen CJ, Lin YW, Hsieh ST, Chen CC: Role of acid-sensing ion channel 3 in sub-acute-phase inflammation. Mol Pain 2009, 5: 1. 10.1186/1744-8069-5-1
Wu WL, Cheng CF, Sun WH, Wong CW, Chen CC: Targeting ASIC3 for pain, anxiety, and insulin resistance. Pharmacol Ther 2012,134(2):127–138. 10.1016/j.pharmthera.2011.12.009
Pollak KA, Swenson JD, Vanhaitsma TA, Hughen RW, Jo D, Light KC, Schweinhardt P, Amann M, Light AR: Exogenously applied muscle metabolites synergistically evoke sensations of muscle fatigue and pain in human subjects. Exp Physiol 2014, 99: 368–380. 10.1113/expphysiol.2013.075812
Desantana JM, da Cruz KM, Sluka KA: Animal models of fibromyalgia. Arthritis Res Ther 2013,15(6):222. 10.1186/ar4402
Molliver D, Immke DC, Fierro L, Pare M, Rice FL, McCleskey EW: ASIC3, an acid-sensing ion channel, is expressed in metaboreceptive sensory neurons. Mol Pain 2005, 1: 35. 10.1186/1744-8069-1-35
Birdsong WT, Fierro L, Williams FG, Spelta V, Naves LA, Knowles M, March-Haffner J, Adelman JP, Almers W, Elde RP, McCleskey EW: Sensing muscle ischemia: coincident detection of acid and ATP via interplay of two ion channels. Neuron 2010, 68: 739–749. 10.1016/j.neuron.2010.09.029
Gautam M, Benson CJ: Acid-sensing ion channels (ASICs) in mouse skeletal muscle afferents are heteromers composed of ASIC1a, ASIC2, and ASIC3 subunits. FASEB J 2013, 27: 793–802. 10.1096/fj.12-220400
Jankowski MP, Rau KK, Ekmann KM, Anderson CE, Koerber HR: Comprehensive phenotyping of group III and IV muscle afferents in mouse. J Neurophysiol 2013, 109: 2374–2381. 10.1152/jn.01067.2012
Lingueglia E, Lazdunski M: Pharmacology of ASIC channels. WIREs Membr Transp Signal 2013, 2: 155–171. 10.1002/wmts.88
Tominaga M, Caterina MJ, Malmberg AB, Rosen TA, Gilbert H, Skinner K, Raumann RE, Basbaum AI, Julius D: The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron 1998, 21: 531–543. 10.1016/S0896-6273(00)80564-4
Frey Law LA, Sluka KA, McMullen T, Lee J, Ardendt-Nielsen L, Graven-Nielsen T: Acidic buffer induced muscle pain evokes referred pain and mechanical hyperalgesia in humans. Pain 2008, 140: 254–264. 10.1016/j.pain.2008.08.014
Mense S: Muscle pain: mechanism and clinical significance. Dtsch Arztebl Int 2008, 105: 214–219.
Huang CW, Tzeng JN, Chen YJ, Tsai WF, Chen CC, Sun WH: Nociceptors of dorsal root ganglion express proton-sensing G-protein-coupled receptors. Mol Cell Neurosci 2007, 36: 195–210. 10.1016/j.mcn.2007.06.010
Chen YJ, Huang CW, Lin CS, Chang WH, Sun WH: Expression and function of proton-sensing G-protein-coupled receptors in inflammatory pain. Mol Pain 2009, 5: 39. 10.1186/1744-8069-5-39
Su YS, Sun WH, Chen CC: Molecular mechanism of inflammatory pain. World J Anesthesiol 2014,3(1):71–81.
Linley JE, Ooi L, Pettinger L, Kirton H, Boyle JP, Peers C, Gamper N: Reactive oxygen species are second messengers of neurokinin signaling in peripheral sensory neurons. Proc Natl Acad Sci USA 2012,109(24):E1578-E1586. 10.1073/pnas.1201544109
Steinhoff MS, von Mentzer B, Geppetti P, Pothoulakis C, Bunnett NW: Tachykinins and their receptors: contributions to physiological control and the mechanisms of diseases. Physiol Rev 2014, 94: 265–301. 10.1152/physrev.00031.2013
Zimmer A, Zimmer AM, Baffi J, Usdin T, Reynolds K, Konig M, Palkovits M, Mezey E: Hypoalgesia in mice with a targeted deletion of the tachykinin 1 gene. Proc Natl Acad Sci USA 1998, 95: 2630–2635. 10.1073/pnas.95.5.2630
This work was supported by Institute of Biomedical Sciences, Academia Sinica, and the Ministry of Science and Technology, Taiwan (NSC102-2325-001-042, NSC102-2321-B-001-056, and NSC102-2320-B-001-021-MY3).
The authors declare that they have no competing interests.
All authors have read and approved the final manuscript. WNC conducted the experiments and analyzed the data. CCC designed the study and wrote the manuscript.